当前位置: X-MOL 学术Semin. Cancer Biol. › 论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
Repurposing of drugs: An attractive pharmacological strategy for cancer therapeutics
Seminars in Cancer Biology ( IF 12.1 ) Pub Date : 2020-05-05 , DOI: 10.1016/j.semcancer.2020.04.006
Anuradha Kirtonia 1 , Kavita Gala 2 , Stina George Fernandes 2 , Gouri Pandya 1 , Amit Kumar Pandey 3 , Gautam Sethi 4 , Ekta Khattar 5 , Manoj Garg 6
Affiliation  

Human malignancies are one of the major health-related issues though out the world and anticipated to rise in the future. The development of novel drugs/agents requires a huge amount of cost and time that represents a major challenge for drug discovery. In the last three decades, the number of FDA approved drugs has dropped down and this led to increasing interest in drug reposition or repurposing. The present review focuses on recent concepts and therapeutic opportunities for the utilization of antidiabetics, antibiotics, antifungal, anti-inflammatory, antipsychotic, PDE inhibitors and estrogen receptor antagonist, Antabuse, antiparasitic and cardiovascular agents/drugs as an alternative approach against human malignancies. The repurposing of approved non-cancerous drugs is an effective strategy to develop new therapeutic options for the treatment of cancer patients at an affordable cost in clinics. In the current scenario, most of the countries throughout the globe are unable to meet the medical needs of cancer patients because of the high cost of the available cancerous drugs. Some of these drugs displayed potential anti-cancer activity in preclinic and clinical studies by regulating several key molecular mechanisms and oncogenic pathways in human malignancies. The emerging pieces of evidence indicate that repurposing of drugs is crucial to the faster and cheaper discovery of anti-cancerous drugs.



中文翻译:

药物再利用:一种有吸引力的癌症治疗药理学策略

人类恶性肿瘤是世界范围内与健康相关的主要问题之一,预计未来还会增加。新药/药剂的开发需要大量的成本和时间,这对药物发现来说是一项重大挑战。在过去的三年中,FDA 批准的药物数量有所下降,这导致人们对药物重新定位或再利用的兴趣日益增加。本综述侧重于利用抗糖尿病药、抗生素、抗真菌药、抗炎药、抗精神病药、PDE 抑制剂和雌激素受体拮抗剂、Antabuse、抗寄生虫药和心血管药物/药物作为抗人类恶性肿瘤的替代方法的最新概念和治疗机会。重新利用已批准的非癌药物是一种有效的策略,可以在诊所以可承受的成本开发新的治疗选择来治疗癌症患者。在目前的情况下,由于可用抗癌药物的高昂成本,全球大多数国家都无法满足癌症患者的医疗需求。其中一些药物通过调节人类恶性肿瘤中的几种关键分子机制和致癌途径,在临床前和临床研究中显示出潜在的抗癌活性。新出现的证据表明,药物的再利用对于更快、更便宜地发现抗癌药物至关重要。由于可用的抗癌药物成本高昂,全球大多数国家都无法满足癌症患者的医疗需求。其中一些药物通过调节人类恶性肿瘤中的几种关键分子机制和致癌途径,在临床前和临床研究中显示出潜在的抗癌活性。新出现的证据表明,药物的再利用对于更快、更便宜地发现抗癌药物至关重要。由于可用的抗癌药物成本高昂,全球大多数国家都无法满足癌症患者的医疗需求。其中一些药物通过调节人类恶性肿瘤中的几种关键分子机制和致癌途径,在临床前和临床研究中显示出潜在的抗癌活性。新出现的证据表明,药物的再利用对于更快、更便宜地发现抗癌药物至关重要。

更新日期:2020-05-05
down
wechat
bug